Payment overview · 2025
General Payments
$305.89
17 reported records · 11 companies
Healthcare provider profile · identity verified
Ralph Lee Abraham, MD
Allopathic & Osteopathic Physicians|Family Medicine · RAYVILLE, LA · NPI 1013962620
Verified facts
What the public records show
CMS Open Payments records show Ralph Lee Abraham, MD received $305.89 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Nexletol.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Nexlizet by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.64 | 20.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.01 | 14.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.26 | 12.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.76 | 10.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.93 | 7.2% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $21.52 | 7.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.78 | 6.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.14 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.12 | 5.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.05 | 5.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.68 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.89 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.64 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.76 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.01 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $30.76 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $14.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 240 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
240 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1142 | 244 |
| Pantoprazole Sodium | Pantoprazole Sodium | 596 | 164 |
| Azithromycin | Azithromycin | 479 | 329 |
| Losartan Potassium | Losartan Potassium | 421 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 415 | 133 |
| Meloxicam | Meloxicam | 414 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 408 | 118 |
| Gabapentin | Gabapentin | 400 | 132 |
| Omeprazole | Omeprazole | 388 | 102 |
| Prednisone | Prednisone | 377 | 209 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 119 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 344 | 144 |
| Montelukast Sodium | Montelukast Sodium | 294 | 88 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 289 | 94 |
| Alprazolam | Alprazolam | 286 | 72 |
| Methylprednisolone | Methylprednisolone | 284 | 223 |
| Furosemide | Furosemide | 278 | 94 |
| Testosterone Cypionate | Testosterone Cypionate | 267 | 67 |
| Lisinopril | Lisinopril | 247 | 74 |
| Eliquis | Apixaban | 240 | 47 |
| Jardiance | Empagliflozin | 237 | 58 |
| Mounjaro | Tirzepatide | 231 | 38 |
| Potassium Chloride | Potassium Chloride | 226 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 224 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 55 |
| Glimepiride | Glimepiride | 213 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 77 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 211 | 170 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 68 |
| Memantine Hcl | Memantine Hcl | 195 | 44 |
| Ozempic | Semaglutide | 179 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 176 | 52 |
| Clonazepam | Clonazepam | 172 | 25 |
| Levofloxacin | Levofloxacin | 168 | 141 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 166 | 49 |
| Estradiol | Estradiol | 162 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 157 | 46 |
| Eszopiclone | Eszopiclone | 147 | 39 |
| Fluconazole | Fluconazole | 145 | 87 |
| Carvedilol | Carvedilol | 143 | 41 |
| Celecoxib | Celecoxib | 141 | 40 |
| Trazodone Hcl | Trazodone Hcl | 132 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 73 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 89 |
| Meclizine Hcl | Meclizine Hcl | 107 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 23 |
| Sertraline Hcl | Sertraline Hcl | 96 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 32 |
| Simvastatin | Simvastatin | 92 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 19 |
| Mupirocin | Mupirocin | 88 | 61 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 24 |
| Metformin Hcl | Metformin Hcl | 87 | 27 |
| Bumetanide | Bumetanide | 86 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 36 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 83 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 17 |
| Pregabalin | Pregabalin | 82 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 79 | 52 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 77 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 17 |
| Entresto | Sacubitril/Valsartan | 76 | 11 |
| Gemfibrozil | Gemfibrozil | 75 | 15 |
| Glipizide | Glipizide | 75 | 17 |
| Ondansetron Odt | Ondansetron | 75 | 47 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 73 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 60 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 26 |
| Methocarbamol | Methocarbamol | 68 | 43 |
| Ofloxacin | Ofloxacin | 68 | 55 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 17 |
| Farxiga | Dapagliflozin Propanediol | 63 | 15 |
| Temazepam | Temazepam | 62 | 14 |
| Ezetimibe | Ezetimibe | 60 | 21 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 20 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 58 | 50 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 13 |
| Tramadol Hcl | Tramadol Hcl | 57 | 25 |
| Finasteride | Finasteride | 56 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 14 |
| Mirtazapine | Mirtazapine | 56 | 15 |
| Alendronate Sodium | Alendronate Sodium | 55 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 50 |
| Trulicity | Dulaglutide | 55 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 21 |
| Ibuprofen | Ibuprofen | 52 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 50 | 22 |
| Nifedipine Er | Nifedipine | 49 | 18 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 49 | 47 |
| Hydrocortisone | Hydrocortisone | 48 | 37 |
| Atenolol | Atenolol | 47 | suppressed |
| Ramipril | Ramipril | 46 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 13 |
| Nexletol | Bempedoic Acid | 44 | 13 |
| Ranolazine Er | Ranolazine | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 11 |
| Buspirone Hcl | Buspirone Hcl | 43 | 13 |
| Cefuroxime | Cefuroxime Axetil | 43 | 41 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 43 | 35 |
| Clonidine | Clonidine | 41 | suppressed |
| Linzess | Linaclotide | 40 | 20 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Premarin | Estrogens, Conjugated | 38 | suppressed |
| Sotalol | Sotalol Hcl | 38 | suppressed |
| Cefdinir | Cefdinir | 37 | 31 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | 12 |
| Metronidazole | Metronidazole | 34 | 28 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Spironolactone | Spironolactone | 32 | 15 |
| Trintellix | Vortioxetine Hydrobromide | 32 | suppressed |
| Cimetidine | Cimetidine | 30 | suppressed |
| Famotidine | Famotidine | 30 | 11 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 20 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | 11 |
| Prempro | Estrogen,con/M-Progest Acet | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.89 · 17 records | Amgen Inc. | BREZTRI, CAPVAXIVE, ELIQUIS, GARDASIL 9, Kerendia, M-M-R II, NEXLETOL, NURTEC ODT, OTEZLA, RELISTOR, REPATHA, REXULTI, SKYCLARYS, UBRELVY, XYOSTED | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error